Mirati Therapeutics & Aadi Bioscience Partner to Evaluate Adagrasib + Nab-sirolimus in Advanced NSCLC and Other Solid Tumors patients with a KRAS[G12C] Mutation October 19, 2022
VBI Vaccines and Agenus Announce Collaboration to Evaluate VBI-1901 in Combination with Balstilimab in a Ph 2 Study in Primary Glioblastoma Patients October 19, 2022
Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs October 19, 2022
Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors October 19, 2022
Allogene Therapeutics Launches CAR T Together™ Initiative Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products October 19, 2022
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Ph 1b STELLAR-002 Trial October 12, 2022
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System October 12, 2022
Kite Receives U.S. FDA Approval Of Viral Vector Manufacturing Facility In Southern California To Produce Commercial Product October 12, 2022
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory NSCLC October 5, 2022
Seagen & LAVA Therapeutics to Advance LAVA-1223, a Gamma Delta BiTE for EGFR-Expressing Solid Tumors October 5, 2022
Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor September 28, 2022
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib September 28, 2022
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines September 28, 2022
SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma September 13, 2022
Oxford BioTherapeutics Announces Collaboration with Agenus toSupport the Clinical Development of OBT’s Antibody DrugConjugate OBT076 in combination with Agenus CPI Balstilimab June 14, 2022
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500) June 13, 2022
Incyclix Bio Announces $30M Series B Financing to Support Clinical Development of INX-315 April 1, 2022
Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates March 5, 2022
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked ADC Candidates December 23, 2021
